Literature DB >> 2771530

Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain.

L J Baraff1, C R Manclark, J D Cherry, P Christenson, S M Marcy.   

Abstract

We investigated the rates of local and systemic reactions following 9920 diphtheria-tetanus toxoids-pertussis immunizations from 25 lots of commercially available, United States-licensed diphtheria-tetanus toxoids-pertussis adsorbed vaccines from four manufacturers as a function of vaccine lot, endotoxin content, pertussis vaccine potency and percent of mouse weight gain. There were significant differences between the rates of reactions by lot for all local and systemic reactions except convulsions and hypotonic hyporesponsive episodes. For these latter reactions there were insufficient cases for analyses. P was less than 0.0001 for local reactions, fever, drowsiness, fretfulness, anorexia and screaming and 0.017 for vomiting. No single lot was associated with the highest or lowest rate of reactions for more than 3 of the 11 reactions. There was a significant positive association of endotoxin unit (EU) content and the percent of vaccine recipients who developed fever (P = 0.004). Fever increased in frequency from 20.6% of children immunized with vaccine lots that contained 2500 EU to 55.1% of children immunized with vaccine lots containing 40,000 EU. There were significant positive associations of all local reactions and pertussis vaccine potency (P = 0.0004), and percent of mouse weight gain (P less than 0.0001). There was also a positive association of percent mouse weight gain and persistent screaming (P = 0.001). However, for the majority of reactions there was no clinically meaningful associations between reaction rates and the biological properties of the vaccine studied.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2771530     DOI: 10.1097/00006454-198908000-00006

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  11 in total

Review 1.  When should vaccination be contraindicated in children?

Authors:  Laura Lane; Arlene Reynolds; Mary Ramsay
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  An overview of the status of acellular pertussis vaccines in practice.

Authors:  A L Lopez; D A Blumberg
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 3.  Hypotonic-hyporesponsive episodes following pertussis vaccination: a cause for concern?

Authors:  Michael S Gold
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 4.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Substitution of the Bordetella pertussis lipid A phosphate groups with glucosamine is required for robust NF-kappaB activation and release of proinflammatory cytokines in cells expressing human but not murine Toll-like receptor 4-MD-2-CD14.

Authors:  Nico Marr; Adeline M Hajjar; Nita R Shah; Alexey Novikov; Cathy S Yam; Martine Caroff; Rachel C Fernandez
Journal:  Infect Immun       Date:  2010-02-22       Impact factor: 3.441

6.  Monokine production following in vitro stimulation of the THP-1 human monocytic cell line with pertussis vaccine components.

Authors:  J Blood-Siegfried; E Crabb Breen; S Takeshita; O Martinez-Maza; D Vredevoe
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

7.  Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation.

Authors:  F Bell; A Martin; C Blondeau; C Thornton; J Chaplais; A Finn
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

8.  Role of whole-cell pertussis vaccine in severe local reactions to the preschool (fifth) dose of diphtheria-pertussis-tetanus vaccine.

Authors:  D W Scheifele; G Bjornson; S H Halperin; L Mitchell; S Boraston
Journal:  CMAJ       Date:  1994-01-01       Impact factor: 8.262

9.  Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid?

Authors:  D Scheifele; L Barreto; W Meekison; R Guasparini; B Friesen
Journal:  CMAJ       Date:  1993-10-15       Impact factor: 8.262

Review 10.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.